Account Wins from the 10/17/06 News Brief

Share this article:
Euro RSCG won ad duties for the osteoporosis drug Boniva following a review in which incumbent Saatchi & Saatchi Consumer Healthcare did not participate, Adweek.com reported. Havas-owned Euro RSCG beat out Omnicom’s BBDO in the final round of the review, the Adweek report said. Boniva is jointly marketed by GlaxoSmithKline and Roche and had a 2005 US media spend of $70 million, according to figures from Nielsen Monitor-Plus. Boniva competes against Eli Lilly’s Evista and Merck’s Fosamax and Procter & Gamble and Sanofi-Aventis’ Acotnel. Last month, a federal judge denied a motion filed by marketers of Actonel to halt Boniva advertising. P&G and Sanofi-Aventis charged that ads for Boniva falsely claimed the drug was proven to be more effective than Actonel. Judge Paul Crotty wrote: “There is no doubt that Boniva is a safe and effective drug which the FDA has approved for the treatment and prevention of osteoporosis in women… nor is Actonel superior to Boniva.”
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.